✦ LIBER ✦

The outcome of intensive induction therapy in patients 70 years with acute myeloid leukemia

✍ Scribed by Gupta, V; Xu, W; Keng, C; Alibhai, S M H; Brandwein, J; Schimmer, A; Schuh, A; Yee, K; Minden, M D

Book ID: 110057171
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 119 KB
Volume: 21
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2404655

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outcome of acute myeloid leukemia patien

Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil

✍ L. C. O. Oliveira; L. G. M. Romano; B. P. A. Prado-Junior; D. T. Covas; E. M. Re 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 221 KB

Gemtuzumab ozogamicin as first-line trea

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia

✍ Wassim McHayleh; Kenneth Foon; Robert Redner; Rajesh Sehgal; Anastasios Raptis; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB 👁 1 views

A phase II study of temozolomide therapy

A phase II study of temozolomide therapy for poor-risk patients aged 60 years with acute myeloid leukemia: low levels of MGMT predict for response

✍ Brandwein, J M; Yang, L; Schimmer, A D; Schuh, A C; Gupta, V; Wells, R A; Alibha 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 103 KB

P-glycoprotein in primary acute myeloid

P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy

✍ Broxterman, H J; Sonneveld, P; van Putten, W J L; Lankelma, J; Eekman, C A; Osse 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 131 KB

Disease biology rather than age is the m

Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy

✍ Vikas Gupta; Kathy Chun; Qi-Long Yi; Mark Minden; Andre Schuh; Richard Wells; Jo 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

Gemtuzumab ozogamicin, mitoxantrone, and

Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

✍ Michael Boyiadzis; Robert L. Redner; Anastasios Raptis; Jing-Zhou Hou; Mounzer A 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 71 KB